Residency · Residency · Endocrinology

Cushing Syndrome - Diagnosis and Management

Overview and Classification

Definitions

Cushing syndrome refers to the clinical syndrome that results from chronic, excessive glucocorticoid exposure from any source. It is essential to distinguish this broad term from Cushing disease, which specifically denotes Cushing syndrome caused by an ACTH-secreting pituitary adenoma, accounting for approximately 70% of all endogenous cases. The most common overall cause of Cushing syndrome, however, is exogenous or iatrogenic exposure through chronic glucocorticoid therapy, a consideration that must always be addressed early in the diagnostic evaluation.

ACTH-Dependent vs ACTH-Independent

The classification of endogenous Cushing syndrome rests on whether the hypercortisolism is driven by excess ACTH production or arises autonomously from the adrenal glands themselves. This distinction is fundamental because it determines the entire subsequent diagnostic and therapeutic pathway.

ACTH-dependent causes account for approximately 80% of endogenous Cushing syndrome. Cushing disease, the most common among these, is responsible for 65-70% of cases. The majority of causative pituitary adenomas are microadenomas, with 60-70% measuring less than 6 mm, which presents considerable challenges for imaging detection. The condition shows a marked female preponderance, with female-to-male ratios ranging from 3:1 to 8:1. Ectopic ACTH syndrome accounts for 10-15% of endogenous cases, with small cell lung cancer being the most common malignant cause and bronchial carcinoid tumors representing the most common occult cause. Other sources of ectopic ACTH include thymic carcinoid tumors, pancreatic neuroendocrine tumors, medullary thyroid carcinoma, and pheochromocytoma. Ectopic CRH secretion is exceedingly rare, constituting less than 1% of cases, and is most often attributable to bronchial carcinoid or pancreatic neuroendocrine tumors.

ACTH-independent causes account for the remaining 20% of endogenous Cushing syndrome. Adrenal adenomas, responsible for 10-15% of cases, are unilateral cortisol-producing lesions that are usually benign. Adrenal carcinoma, comprising approximately 5% of cases, tends to present as a large mass exceeding 4-6 cm at diagnosis and is frequently characterized by mixed hormone secretion, particularly cortisol combined with androgens, and an aggressive clinical course. Bilateral macronodular adrenal hyperplasia (BMAH) represents a fascinating entity in which aberrant receptor expression on adrenal cells -- including receptors for glucose-dependent insulinotropic peptide (GIP), luteinizing hormone/human chorionic gonadotropin, serotonin, vasopressin, or beta-adrenergic agonists -- drives autonomous cortisol production. Familial cases of BMAH have been linked to ARMC5 gene mutations. Primary pigmented nodular adrenocortical disease (PPNAD), characterized by bilateral micronodular hyperplasia, occurs in young patients and is associated with Carney complex, which is caused by PRKAR1A mutations.

Clinical Features

Signs and Symptoms (Discriminatory Features in Bold)

The clinical presentation of Cushing syndrome reflects the widespread metabolic, catabolic, and immunosuppressive effects of chronic glucocorticoid excess. While many features overlap with common conditions such as obesity and metabolic syndrome, certain findings are highly discriminatory and should prompt diagnostic evaluation.

Proximal myopathy, present in 50-80% of patients, manifests as difficulty rising from a chair or climbing stairs and reflects the catabolic effect of cortisol on skeletal muscle. Wide purple or violaceous striae exceeding 1 cm in width, found in 50-70% of patients, are among the most specific physical findings. These typically appear on the abdomen, axillae, and thighs and must be distinguished from the thin, pink or white striae commonly seen with ordinary obesity or weight gain. Easy bruising without significant trauma, occurring in 35-65% of patients, results from the thinning and fragility of skin induced by cortisol's catabolic effects on dermal collagen. Facial plethora, present in 70-90% of cases, produces the characteristic round "moon facies" with rubor.

Central or truncal obesity with relative thinning of the extremities is present in approximately 90% of patients and is often accompanied by supraclavicular and dorsocervical fat pads, the latter classically referred to as a "buffalo hump." Hirsutism and acne affect 70-80% of women with Cushing syndrome, with more severe androgenic features suggesting adrenal carcinoma as the underlying cause. Hypertension, found in approximately 80% of patients, results from the mineralocorticoid effect of cortisol at high concentrations, which overwhelms the inactivating enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2). Glucose intolerance or frank diabetes mellitus develops in 40-45% of patients.

Osteoporosis and fractures, particularly vertebral compression fractures, are found in 30-50% of patients, and bone density may underestimate the true fracture risk because cortisol impairs bone quality independent of density. Neuropsychiatric manifestations are exceedingly common, with depression affecting 50-70% of patients, along with cognitive impairment, insomnia, emotional lability, and, less commonly, psychosis. Hypogonadism manifests as oligomenorrhea or amenorrhea in women and decreased libido or erectile dysfunction in men. Recurrent infections and poor wound healing reflect the profound immunosuppressive effects of cortisol excess.

Two clinical features deserve particular attention for their diagnostic implications. Hyperpigmentation occurs only in ACTH-dependent Cushing syndrome when ACTH levels are very high, as is particularly characteristic of ectopic ACTH secretion. Hypokalemic metabolic alkalosis is a hallmark of ectopic ACTH syndrome, in which extremely high cortisol levels overwhelm 11-beta-HSD2 capacity, allowing cortisol to activate the mineralocorticoid receptor and produce potent mineralocorticoid effects.

<image>A clinical features illustration of Cushing syndrome showing a full-body figure with labeled signs. Head/face: moon facies with facial plethora, acne, hirsutism in a female patient. Trunk: central obesity, supraclavicular fat pads, buffalo hump (dorsocervical fat pad), wide purple striae on abdomen. Extremities: thin arms and legs with proximal muscle wasting, easy bruising on forearms. Additional insets: (1) close-up of wide purple striae versus normal pink striae for comparison, (2) thin skin with visible bruising on forearm, (3) vertebral compression fractures on lateral spine X-ray. Include a box listing metabolic complications: hypertension, diabetes, osteoporosis, hypokalemia, dyslipidemia. Use realistic medical illustration style.</image>

Diagnostic Approach

Step 1: Confirm Hypercortisolism (At Least 2 Positive Tests)

The diagnostic workup for Cushing syndrome proceeds in a stepwise fashion: first confirming the presence of hypercortisolism, then determining its ACTH dependence, and finally identifying the precise source. At least two abnormal first-line screening tests are required before proceeding to the etiologic workup.

First-Line Screening Tests

The 24-hour urinary free cortisol (UFC) collection, performed twice, measures unbound cortisol filtered by the kidney and provides an integrated assessment of daily cortisol production. Values exceeding three times the upper limit of normal are highly suggestive, while mild elevations of one to two times the upper limit are less specific. The adequacy of the 24-hour collection must be verified by checking urinary creatinine. False-positive elevations can occur with high fluid intake, pregnancy, depression, alcoholism, and obesity.

Late-night salivary cortisol, also performed twice, exploits the fact that loss of the normal circadian cortisol nadir is the earliest biochemical abnormality in Cushing syndrome. Samples are collected at 23:00 to midnight, and the assay is a convenient outpatient test. False-positive results may occur in shift workers, smokers (salivary contamination), and critically ill patients.

The 1 mg overnight dexamethasone suppression test (DST) involves administration of dexamethasone 1 mg orally at 23:00, with serum cortisol measurement at 08:00 the following morning. Normal suppression is defined as cortisol below 1.8 mcg/dL (50 nmol/L). This test has high sensitivity (approximately 95%) but lower specificity, and false-positive results can occur in obesity, depression, alcoholism, estrogen or oral contraceptive use (which increases cortisol-binding globulin), and with drugs that induce CYP3A4-mediated dexamethasone metabolism, such as phenytoin, rifampin, and carbamazepine. The 2-day low-dose DST (Liddle test), using dexamethasone 0.5 mg every 6 hours for 48 hours with cortisol measurement at 08:00 on day three, is more specific but less commonly used as an initial screen.

Confirming Tests

At least two abnormal first-line tests are required before proceeding to the etiology workup. When one test is abnormal and another normal, repeat testing should be performed, and cyclic Cushing syndrome (intermittent hypercortisolism) should be considered. Midnight serum cortisol measured in the inpatient setting is highly specific -- a sleeping cortisol above 1.8 mcg/dL or an awake cortisol above 7.5 mcg/dL is significant -- but requires hospitalization.

The distinction between true Cushing syndrome and pseudo-Cushing states is a frequent clinical challenge. Depression, alcoholism, obesity, and poorly controlled diabetes can all produce mild cortisol elevation and partial resistance to dexamethasone suppression. The CRH-dexamethasone test (dex-CRH test) is particularly valuable in this setting: dexamethasone 0.5 mg is given every 6 hours for 48 hours, followed by CRH 1 mcg/kg intravenously at the 48-hour plus 2-hour mark. A cortisol level exceeding 1.4 mcg/dL at 15 minutes post-CRH suggests true Cushing syndrome rather than a pseudo-Cushing state.

Step 2: Determine ACTH Dependence

Once hypercortisolism is confirmed, plasma ACTH measurement -- obtained on two occasions, with samples properly collected on ice to prevent degradation -- directs the subsequent workup. An ACTH level below 5 pg/mL (1.1 pmol/L) indicates ACTH-independent disease and should prompt adrenal imaging with CT. Values between 5 and 20 pg/mL are equivocal, and CRH stimulation testing may be helpful. An ACTH level above 20 pg/mL (4.4 pmol/L) confirms ACTH-dependent disease and necessitates differentiation between a pituitary and ectopic source.

Step 3: Differentiate Cushing Disease from Ectopic ACTH

CRH Stimulation Test

The CRH stimulation test involves intravenous administration of ovine or human CRH at 1 mcg/kg, with measurement of ACTH and cortisol at multiple time points before and after injection. In Cushing disease, pituitary corticotroph adenomas retain partial CRH responsiveness, producing a greater than 35-50% increase in ACTH and/or a greater than 20% increase in cortisol. In ectopic ACTH syndrome, the source tumors typically do not express CRH receptors and show no response, although exceptions exist, notably bronchial carcinoid tumors, which may demonstrate CRH responsiveness.

High-Dose Dexamethasone Suppression Test (8 mg Overnight or 2-Day)

The 8 mg overnight dexamethasone suppression test involves dexamethasone 8 mg at 23:00 with morning cortisol measurement; suppression of cortisol by more than 50% suggests Cushing disease. However, the diagnostic accuracy of this test is limited at approximately 80%, and it has been largely replaced by inferior petrosal sinus sampling at many referral centers. It remains useful when IPSS is unavailable.

Pituitary MRI

Gadolinium-enhanced thin-cut MRI of the pituitary identifies an adenoma in only 50-60% of patients with confirmed Cushing disease, because many causative adenomas are microadenomas smaller than 6 mm, which fall below the detection threshold of current imaging. A negative MRI emphatically does not exclude Cushing disease; 40-50% of patients with confirmed pituitary-dependent disease have negative or equivocal MRI findings. When a visible microadenoma larger than 6 mm is concordant with the biochemical picture, it may be sufficient to proceed to surgery without IPSS.

Inferior Petrosal Sinus Sampling (IPSS) - Gold Standard

IPSS involves bilateral simultaneous catheterization of the inferior petrosal sinuses along with peripheral venous sampling. ACTH is measured before and after CRH stimulation. A central-to-peripheral ACTH ratio of 2.0 or greater at baseline or 3.0 or greater after CRH stimulation confirms a pituitary source with sensitivity of 94-99% and specificity of 95-100%. Lateralization, assessed by an IPS ratio exceeding 1.4, can predict the side of the tumor and guide surgical exploration, though it is less reliable than central confirmation. IPSS is indicated in confirmed ACTH-dependent Cushing syndrome with negative or equivocal MRI, or when an MRI lesion smaller than 6 mm is discordant with the biochemistry. Complications are rare but include venous thrombosis, brainstem stroke (less than 0.5%), cranial nerve VI palsy, and groin hematoma. This procedure must be performed at an experienced center, as outcomes are highly technique-dependent.

<image>A comprehensive diagnostic algorithm for Cushing syndrome. Start with clinical suspicion. Step 1: Screen with at least 2 tests (24h UFC, late-night salivary cortisol, 1mg DST). If 2+ positive → confirmed hypercortisolism. Step 2: Measure ACTH. If ACTH suppressed (<5 pg/mL) → ACTH-independent → adrenal CT → branch to adrenal adenoma, carcinoma, or bilateral disease (BMAH, PPNAD). If ACTH elevated (>20 pg/mL) → ACTH-dependent → pituitary MRI. If MRI shows clear adenoma >6mm concordant with biochemistry → surgery. If MRI negative/equivocal → IPSS with CRH. If central:peripheral ratio ≥3 post-CRH → Cushing disease → TSS. If ratio <3 → ectopic ACTH → CT chest/abdomen, octreotide scan, 68Ga-DOTATATE PET/CT. Include a side box for pseudo-Cushing differential (depression, alcoholism, obesity) and dex-CRH test. Use clinical flowchart format with decision diamonds.</image>

Management

Cushing Disease - Surgery

Transsphenoidal surgery (TSS) is the first-line treatment for Cushing disease. Remission rates range from 65-90% for microadenomas to 50-65% for macroadenomas, with experienced neurosurgical expertise being essential. Post-operative assessment relies on serum cortisol measurement: a cortisol level below 2 mcg/dL within 72 hours, measured in the morning after withholding glucocorticoid replacement for 24 hours, predicts remission. Successful surgery results in adrenal insufficiency, which is actually an expected and favorable sign; patients require glucocorticoid replacement for months until the hypothalamic-pituitary-adrenal (HPA) axis recovers, a process that may take 6-18 months. Despite initial remission, recurrence develops in 10-25% of patients at 10 years, necessitating long-term surveillance with annual late-night salivary cortisol and/or UFC measurements.

Cushing Disease - Medical Therapy

Medical therapy is indicated for patients who have failed surgery, are awaiting surgery, are poor surgical candidates, or who require bridging to definitive therapy. The available agents fall into three categories: steroidogenesis inhibitors, pituitary-directed agents, and glucocorticoid receptor antagonists.

Steroidogenesis Inhibitors

Ketoconazole, dosed at 200-400 mg twice to three times daily (maximum 1200 mg/day), inhibits multiple cytochrome P450 enzymes including CYP11A1, CYP17, and CYP11B1. It achieves cortisol normalization in 50-70% of patients but carries risks of hepatotoxicity (requiring liver function monitoring), significant drug interactions as a CYP3A4 inhibitor, and QTc prolongation.

Metyrapone, administered at 250-1000 mg three to four times daily, inhibits 11-beta-hydroxylase and has a rapid onset of action, achieving cortisol normalization in 50-75% of patients. Its side effects reflect the accumulation of upstream steroid precursors, including hirsutism and acne from androgens, hypertension from deoxycorticosterone and 11-deoxycortisol, and hypokalemia.

Osilodrostat (Isturisa), dosed at 2-7 mg twice daily, is a potent inhibitor of both 11-beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2). The LINC 3 and LINC 4 trials demonstrated cortisol normalization rates of 66-77%. Side effects include adrenal insufficiency, hypokalemia, QTc prolongation, and hirsutism.

Levoketoconazole (Recorlev), a stereoisomer of ketoconazole with a potentially improved hepatic safety profile, achieves cortisol normalization in approximately 30% of patients at doses of 200-600 mg twice daily, as demonstrated in the SONICS trial.

Mitotane is an adrenolytic agent that destroys the adrenal cortex. For Cushing syndrome, it is dosed at 2-3 g/day with a narrow therapeutic window requiring blood levels of 14-20 mcg/mL. Its slow onset of action (weeks to months) and severe side effects, including gastrointestinal and neurological toxicity along with adrenal insufficiency requiring supraphysiologic glucocorticoid replacement, make it primarily suitable for adrenal carcinoma.

Etomidate, an intravenous anesthetic agent, administered as a continuous sub-anesthetic infusion at 0.03 mg/kg/hr, inhibits 11-beta-hydroxylase and can achieve rapid cortisol lowering within hours. It requires ICU monitoring and is reserved for acute severe Cushing presentations, including crisis and perioperative management, where it can be life-saving.

Pituitary-Directed Agents

Pasireotide (Signifor) is a somatostatin receptor ligand that targets SSTR5, which is expressed on corticotroph adenomas. Available as 0.6-0.9 mg subcutaneously twice daily or as a long-acting release formulation at 10-40 mg monthly, it achieved cortisol normalization in approximately 25% of patients in the PASPORT trial. However, it carries a significant risk of hyperglycemia, affecting more than 70% of patients, often necessitating GLP-1 receptor agonist therapy, along with hepatic enzyme elevation.

Cabergoline, a dopamine agonist used off-label at doses of 1-7 mg weekly, achieves cortisol normalization in approximately 25-35% of patients. Its favorable tolerability profile makes it a useful adjunctive agent.

Glucocorticoid Receptor Antagonist

Mifepristone (Korlym) is a competitive glucocorticoid receptor antagonist approved by the FDA for the treatment of hyperglycemia or diabetes associated with Cushing syndrome. Dosed at 300-1200 mg daily, it has a unique monitoring challenge: because it blocks the glucocorticoid receptor, cortisol levels actually rise through loss of negative feedback, and ACTH levels increase as well. Therefore, dosing cannot be guided by cortisol measurements; instead, clinical monitoring and glucose levels must be used. Hypokalemia can develop because high cortisol levels activate the mineralocorticoid receptor. As an anti-progesterone agent, it causes endometrial thickening and should be avoided in premenopausal women not on contraception. Drug interactions are significant, as mifepristone is both a CYP3A4 substrate and inhibitor.

Relacorilant, a selective glucocorticoid receptor antagonist without anti-progesterone activity, has shown improvement in metabolic parameters in Phase 3 data (GRACE study) and may offer a better side effect profile than mifepristone.

Bilateral Adrenalectomy

Bilateral adrenalectomy provides definitive treatment for refractory Cushing syndrome from any cause. It produces immediate and complete cortisol reduction but requires lifelong glucocorticoid and mineralocorticoid replacement. The laparoscopic approach is preferred, with remission rates of 95-100%. The principal concern following bilateral adrenalectomy for Cushing disease is Nelson syndrome, which occurs in 15-25% of patients. This condition involves progressive expansion of the corticotroph tumor, driven by loss of cortisol-mediated negative feedback, resulting in rising ACTH levels, tumor growth, and hyperpigmentation. Patients require monitoring with serial ACTH levels and MRI. Prophylactic pituitary radiation may reduce the risk, though this remains a subject of debate.

Radiation Therapy

Stereotactic radiosurgery, using Gamma Knife or CyberKnife technology, can be applied when the tumor is more than 3-5 mm from the optic chiasm. It achieves cortisol normalization in 50-70% of patients, though this occurs gradually over 3-5 years. Fractionated radiotherapy, delivering 45-54 Gy, is used for tumors too close to the chiasm and has similar long-term efficacy. Hypopituitarism develops in 30-50% of patients at 10 years, representing a significant long-term trade-off. Radiation therapy is typically reserved for recurrent disease after surgery or as an adjunct to medical therapy.

Ectopic ACTH Syndrome

The management of ectopic ACTH syndrome centers on localizing and resecting the source tumor, which is curative when the tumor is resectable. Bronchial carcinoid tumors have the best surgical outcomes. When the ectopic source is occult, thin-cut chest CT and 68Ga-DOTATATE PET/CT (which is superior to octreotide scintigraphy) are employed for localization, though repeated imaging over months to years may be necessary. Steroidogenesis inhibitors such as ketoconazole, metyrapone, and osilodrostat provide cortisol control while the source is being identified or when the tumor is not resectable. Bilateral adrenalectomy is reserved for cases where the source cannot be found or resected and medical therapy is inadequate.

Adrenal Causes

Adrenal adenomas are treated with unilateral laparoscopic adrenalectomy, which is curative. Post-operative adrenal insufficiency occurs until the contralateral adrenal recovers, a process that may take months. Adrenal carcinoma requires surgery combined with mitotane, with or without chemotherapy using the EDP-M regimen (etoposide, doxorubicin, cisplatin plus mitotane); prognosis is poor in metastatic disease, as demonstrated in the FIRM-ACT trial. BMAH is managed with bilateral adrenalectomy when symptomatic, or with medical therapy or subtotal adrenalectomy in selected cases. PPNAD in the context of Carney complex is treated with bilateral adrenalectomy, accompanied by screening for associated features including cardiac myxomas, skin lesions, and other endocrine tumors.

Complications and Comorbidity Management

Cardiovascular Risk

The cardiovascular risk profile in Cushing syndrome encompasses hypertension, dyslipidemia, diabetes, and hypercoagulability. The risk of venous thromboembolism is increased approximately 10-fold, and prophylaxis should be considered perioperatively; some centers recommend prophylaxis during active Cushing syndrome. Atherosclerosis is accelerated, and cardiovascular risk may remain elevated for years after Cushing syndrome achieves remission.

Bone Health

Vertebral fractures occur in 30-50% of patients, and DXA may significantly underestimate fracture risk because cortisol adversely affects bone quality independent of bone mineral density. DXA should be performed at diagnosis along with fracture risk assessment, and bisphosphonate therapy should be considered when fractures or significant osteoporosis are present, particularly if the Cushing syndrome is not immediately curable.

Infection Risk

Patients with active Cushing syndrome face increased susceptibility to opportunistic infections. Pneumocystis jirovecii pneumonia (PJP) prophylaxis should be provided when the patient is severely Cushingoid, particularly in the setting of ectopic ACTH syndrome with very high cortisol levels. It is important to recognize that immunosuppression may persist for weeks to months following cortisol normalization.

Post-Cure Recovery

Glucocorticoid withdrawal syndrome is a common and often distressing post-remission phenomenon, characterized by fatigue, myalgias, arthralgias, and mood changes that occur even at physiologic replacement doses and may persist for months. Weight redistribution and metabolic improvement gradually occur over 6-12 months. Neuropsychiatric recovery may be incomplete, as cognitive deficits may not fully resolve and brain volume reduction is only partially reversible. Bone density improvement occurs over 2-3 years, accompanied by a gradual decrease in fracture risk.

Key Clinical Pearls

• Late-night salivary cortisol is the most sensitive initial screening test for Cushing syndrome; loss of diurnal variation is the earliest biochemical abnormality
• A negative pituitary MRI does NOT exclude Cushing disease; 40-50% of confirmed Cushing disease has a negative or equivocal MRI; IPSS is required when MRI is non-diagnostic
• Ectopic ACTH syndrome should be suspected when: very high ACTH (>200 pg/mL), severe hypokalemia, rapid onset of symptoms, no pituitary lesion on MRI, and no response to CRH stimulation
• Mifepristone is the only GR antagonist available; its use requires clinical monitoring because cortisol levels RISE (feedback blockade), making biochemical monitoring impossible
• Nelson syndrome (corticotroph tumor progression) occurs in 15-25% of patients after bilateral adrenalectomy for Cushing disease; prophylactic pituitary radiation is controversial but should be discussed
• Etomidate IV infusion (sub-anesthetic dose) is the fastest-acting agent for acute cortisol lowering and can be life-saving in critical Cushing presentations; requires ICU monitoring

References

1. Nieman LK, et al. "The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2008;93(5):1526-1540.
2. Nieman LK, et al. "Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2015;100(8):2807-2831.
3. Fleseriu M, et al. "Consensus on Diagnosis and Management of Cushing's Disease." Lancet Diabetes Endocrinol. 2021;9(12):847-875.
4. Lacroix A, et al. "Cushing's Syndrome." Lancet. 2015;386(9996):913-927.
5. Pivonello R, et al. "Complications of Cushing's Syndrome: State of the Art." Lancet Diabetes Endocrinol. 2016;4(7):611-629.

Read this lecture as Markdown